As cardiomyopathy market expands, Alnylam offers look at Phase 1 data in healthy volunteers

Alnylam’s experimental RNAi treatment for a rare form of cardiomyopathy has shown signs of efficacy in an early-stage trial of healthy volunteers, but analysts said development could be challenging as new treatments near the market ...